Sciwind Biosciences diabetes drug approved in China

SHANGHAI, Jan 30 (Reuters) - Sciwind Biosciences' type 2 diabetes treatment Xianyida was approved for use in China, the company said on Friday, adding another participant to a hot sector in the world's second-largest pharmaceutical market. China has the highest number of adults with diabetes in the world, according to estimates from the International Diabetes Federation, and drugmakers including